2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108303
    Neridronate sodium 80729-79-9 98%
    Neridronate sodium is a bisphosphonate. Bisphosphonates initiate the Apoptotic process. Neridronate sodium reduces the levels of bone resorption, bone turnover markers, the degree of back pain, and the risk of fractures. Neridronate sodium inhibits capillary tube formation. Neridronate sodium itself has weak anticancer activity, but liposomal encapsulation enhances this activity. Neridronate sodium can be used in research related to demineralizing metabolic bone diseases, thalassemia-associated osteoporosis, chronic inflammatory diseases, cancer, and osteogenesis imperfecta.
    Neridronate sodium
  • HY-108327
    PF-05020182 1354712-92-7 98%
    PF-05020182 is an orally active opener for Kv7 channel, that activates human Kv7.2/7.3, Kv7.4 and Kv7.3/7.5 with EC50 of 334, 625 and 588 nM, respectively. PF-05020182 exhibits anticonvulsant activity in rats corneal electric shock-induced tonic seizure (MES) models. PF-05020182 is blood-brain barrier (BBB) penetrable.
    PF-05020182
  • HY-108400
    SCH-23390 maleate 87134-87-0 98%
    SCH-23390 maleate (R-(+)-SCH-23390 maleate) is a potent and selective dopamine D1-like receptor antagonist with Kis of 0.2 nM and 0.3 nM for the D1 and D5 receptor, respectively. SCH-23390 maleate is a potent and high efficacy human 5-HT2C receptor agonist with a Ki of 9.3 nM. SCH-23390 maleate also binds with high affinity to the 5-HT2 and 5-HT1C receptors. SCH-23390 maleate inhibits G protein-coupled inwardly rectifying potassium (GIRK) channels with an IC50 of 268 nM.
    SCH-23390 maleate
  • HY-108438
    TCS 2210 1201916-31-5 98%
    TCS 2210 (compound 1) is a neuronal differentiation inducer in mesenchymal stem cells (MSCs). TCS 2210 increases expression of the neuronal markers β-III tubulin and neuron-specific enolase (NSE).
    TCS 2210
  • HY-108459
    6-Iodonordihydrocapsaicin 859171-97-4 98%
    6-Iodonordihydrocapsaicin is a TRPV1 antagonist. 6-Iodonordihydrocapsaicin functionally blocks TRPV1-mediated responses, including capsaicin-induced ion currents in dorsal root ganglion neurons and distension-induced firing of jejunal spinal afferent fibers in mice. 6-Iodonordihydrocapsaicin can be used in the research of visceral pain and anxiety disorders.
    6-Iodonordihydrocapsaicin
  • HY-108480
    SDZ NKT 343 180046-99-5 98%
    SDZ NKT 343 is a selective, orally active NK1 receptor antagonist with an IC50 of 0.62 nM against human NK1 receptor. SDZ NKT 343 has good analgesic activity.
    SDZ NKT 343
  • HY-108514
    (±)-PPCC hemioxalate 932736-91-9 98%
    (±)-PPCC hemioxalate is a compound that has the ability to regulate the activity of the sigma-1 receptor. (±)-PPCC hemioxalate can selectively bind sigma-1 protein (s1), and then activate s1 receptor leading to dissociation of s1-BIP complex to regulate ER-mitochondrial calcium signaling, which plays an important role in cell bioenergy and cell survival. (±)-PPCC hemioxalate can be used to study sigma-1 receptors in cocaine addiction, forgetting, pain, depression, Alzheimer's disease, stroke, and cancer.
    (±)-PPCC hemioxalate
  • HY-108576
    Linopirdine dihydrochloride 113168-57-3 98%
    Linopirdine dihydrochloride is a agonist of capsaicin receptor TRPV1. Linopirdine increases the intracellular calcium concentration in HEK293 cells. Linopirdine dihydrochloride exerts an excitatory action on mammalian nociceptors.
    Linopirdine dihydrochloride
  • HY-108578
    RuBi-4AP 851956-02-0 98%
    RuBi-4AP, a derivative of 4-aminopyridine (4AP; HY-B0604), is a caged Kv channel blocker. RuBi-4AP contains a photolabile protecting group, allowing its effect to be controlled precisely in both space and time with light. RuBi-4AP can be used for the research of neuronal excitability, synaptic transmission, and signal propagation.
    RuBi-4AP
  • HY-108654
    PSB 0474 917567-60-3 98%
    PSB 0474 (3-phenacyl-UDP) is a UDP (HY-113359) analog and selective P2Y6 receptor agonist, with an EC50 value of 70 nM for the hP2Y6 receptor. PSB 0474 activates Phospholipase C-coupled receptors to increase intracellular inositol phosphate levels. PSB 0474 enhances NO release by upregulating inducible iNOS and induces Apoptosis. PSB 0474 increases micturition frequency in urine of anesthetized rats, without altering bladder contraction amplitude/duration or causing urothelial damage. PSB 0474 can be used in studies related to chronic brain inflammation.
    PSB 0474
  • HY-108657
    MRS2279 367909-40-8 98%
    MRS2279 is a selective and high affinity P2Y1 receptor antagonist, with a Ki of 2.5 nM and an IC50 of 51.6 nM. MRS2279 competitively inhibits ADP-promoted platelet aggregation with an apparent affnity (pKB=8.05).
    MRS2279
  • HY-108663
    5-OMe-UDP 1207530-98-0 98%
    5-OMe-UDP (5-methoxyuridine 5'-trihydrogen diphosphate) is a P2Y6 receptor agonist (EC50=0.08 μM). 5-OMe-UDP activates the P2Y6 receptor by binding to it, which triggers signaling pathways within the cell. This activation can lead to an increase in intracellular calcium ion concentration, which in turn regulates cellular function. The methoxy groups of 5-OMe-UDP provide additional activity and selectivity, contributing to the binding of 5-OMe-UDP to the P2Y6 receptor. 5-OMe-UDP can be used to study diseases related to P2Y6 receptor function, such as diabetes, inflammatory bowel disease, Alzheimer's disease, etc.
    5-OMe-UDP
  • HY-108920
    4-Chlorokynurenine 153152-32-0 99.94%
    4-Chlorokynurenine (4-Cl-KYN) is a prodrug of 7-Chlorokynurenic acid (NMDA receptor antagonist) (HY-100811). 4-Chlorokynurenine has orally activity and blood-brain permeability. 4-Chlorokynurenine can reduce depressive symptoms and neurotoxicity. 4-Chlorokynurenine can be used for the research of neurological disease, such as depression and seizure.
    4-Chlorokynurenine
  • HY-108942
    ASP5854 851087-60-0 98%
    ASP5854 is an orally active, blood-brain barrier permeable adenosine A1/A2a dual receptor antagonist. ASP5854 blocks receptor activity and agonist-induced intracellular calcium elevation, and exhibits the characteristic of slow dissociation from striatal A2a receptors in primates. ASP5854 reverses catalepsy, enhances cognitive ability, improves motor function and exerts neuroprotective effects, while also alleviating dyskinesia and increasing contralateral turning behavior. ASP5854 is mainly used in studies related to ischemic stroke and Parkinson's disease.
    ASP5854
  • HY-108960
    PPADS 149017-66-3 98%
    PPADS is a P2X receptor (P2X Receptor) antagonist and a reversible competitive antagonist of NAADP receptors, with IC50 values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat P2X1 and P2X3 receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain.
    PPADS
  • HY-108973
    Ifoxetine hemisulfate 98518-48-0 98%
    Ifoxetine (CGP 15210G) hemisulfate is an inhibitor of 5-HT reuptake. Ifoxetine hemisulfate specifically and selectively blocks the 5-HT reuptake in the brain without affecting the 5-HT uptake processes in the periphery (blood platelets). Ifoxetine hemisulfate inhibits the uptake of radiolabelled 5-HT into rat brain synaptosomes in vitro or ex vivo. Ifoxetine hemisulfate has antidepressant properties.
    Ifoxetine hemisulfate
  • HY-108976
    Raclopride tartrate 98185-20-7 98%
    Raclopride tartrate is a selective dopamine D2/D3 receptor antagonist with potential antipsychotic effects. Raclopride tartrate binds to D2 and D3 receptors with Kis of 1.8 nM and 3.5 nM, respectively.
    Raclopride tartrate
  • HY-108977
    VUF 8430 98021-17-1 98%
    VUF 8430 is a potent and selective histamine H4 receptor agonist with a Ki of 31.6 nM and an EC50 of 50 nM.
    VUF 8430
  • HY-108985
    Trazium esilate 97110-59-3 98%
    Trazium esilate (EGYT-3615) is an antidepressant, which influences the central dopaminergic system. Trazium esilate synergizes amphetamine, potentiates stereotypy and hypermotility. Trazium esilate blocks Apomorphine (HY-12723)-induced hypothermic and the stereotypy, and Bulbocapnine (HY-W436270)-induced cataleptic state. Trazium esilate enhances the effect of Norepinephrine (HY-13715) on isolated vas deferens of the rat.
    Trazium esilate
  • HY-109006
    Ilmetropium iodide 129109-88-2 98%
    Ilmetropium iodide is an anticholinergic agent. Ilmetropium iodide selectively blocks M-cholinergic receptors of bronchial muscle, reduces or prevents bronchoconstrictor response associated with both cholinergic stimulation, as well as the impact of the factors that provoke bronchospasm. Strength and selectivity of ilmetropium iodide action substantially exceeds Atropine sulfate (HY-B1205A) and Ipratropium bromide (HY-B0241).
    Ilmetropium iodide
Cat. No. Product Name / Synonyms Application Reactivity